
AADI LLC Profile last edited on: 3/16/21
CAGE: 6LMB3
UEI: E1BJRNH2DDG6
Business Identifier: MTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 33
County: Los Angeles
Congr. District: 33
County: Los Angeles
Public Profile
AADi, LLC, - also dba as AADI Biosciences - is a clinical stage biopharmaceutical company structured around in-house invented, lead product TARZIFYX⢠- sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009 -- mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation and improved efficacy over other mTOR inhibitors in preclinical models. With mTOR as a therapeutic target well recognized in oncology, Aadi is focused on developing the full potential of albumin-bound sirolimus in therapeutic areas and diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. These indications include oncology, cardiovascular, CNS, mitochondrial disease and diseases of ageing.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2015 | 2 | NIH | $1,565,974 | |
Project Title: Investigation of a Nanoparticle Albumin-Bound Mtor Inhibitor, Nab-Rapamycin for T |
Key People / Management
Neil Desai -- Founder, CEO and President
Mitchall Clark -- Regulatory Affairs and Quality Advisor SVP, Regulatory Affairs and Quality Assur
Berta Grigorian -- VP Clinical Operations
Madhu Kalaimalai
Mitchall Clark -- Regulatory Affairs and Quality Advisor SVP, Regulatory Affairs and Quality Assur
Berta Grigorian -- VP Clinical Operations
Madhu Kalaimalai